Newbridge Financial Boosts Eli Lilly Stake by 49%

Institutional investor adds 3,404 shares to its Eli Lilly holdings in Q3

Mar. 14, 2026 at 9:22am

Got story updates? Submit your updates here. ›

Newbridge Financial Services Group Inc. increased its stake in pharmaceutical giant Eli Lilly and Company by 49% during the third quarter, according to a recent 13F filing. The institutional investor now owns 10,355 shares of Eli Lilly's stock, worth approximately $7.9 million as of the end of the quarter.

Why it matters

Eli Lilly is one of the world's largest pharmaceutical companies, known for developing innovative medicines across a range of therapeutic areas. Institutional investors closely monitor and adjust their positions in Lilly's stock, as the company's performance and pipeline can significantly impact its share price and market valuation.

The details

Newbridge Financial Services Group Inc. purchased an additional 3,404 shares of Eli Lilly during the third quarter, bringing its total position to 10,355 shares. This represents approximately 1.2% of Newbridge's overall investment portfolio. Eli Lilly and Company is now the 20th largest holding in Newbridge's fund.

  • Newbridge Financial Services Group Inc. filed its 13F report for the third quarter on October 15, 2026.

The players

Newbridge Financial Services Group Inc.

An institutional investment firm that manages a diversified portfolio of stocks, bonds, and other assets on behalf of its clients.

Eli Lilly and Company

A global pharmaceutical company that researches, develops, manufactures, and commercializes a broad range of medicines and therapies for patients worldwide.

Got photos? Submit your photos here. ›

The takeaway

Newbridge Financial's increased stake in Eli Lilly reflects the institutional investor's confidence in the pharmaceutical company's long-term growth potential. As a major player in the industry, Lilly's stock performance and pipeline developments are closely watched by the investment community.